Adding Tobramycin to Vancomycin Powder Does Not Reduce Tibial Fracture Infections

The Persistent Challenge of Fracture-Related Infections

Fracture-related infections remain a devastating complication in orthopedic trauma, leading to increased morbidity, prolonged hospital stays, and the potential need for amputation [1, 2]. To mitigate this risk, surgeons increasingly rely on local antibiotic delivery systems, such as intrawound powders or antibiotic-impregnated calcium sulfate, to achieve high tissue concentrations without systemic toxicity [3]. While local vancomycin administration has become a common prophylactic strategy to target gram-positive pathogens in high-risk fractures, the optimal regimen remains heavily debated [4, 5]. Because complex periarticular injuries often face polymicrobial threats, clinicians frequently consider adding agents with gram-negative coverage, though the clinical efficacy of this dual-powder approach has lacked rigorous validation. A newly published randomized clinical trial of 1528 patients now provides clear evidence that adding 1.2 g of intrawound tobramycin to 1.0 g of vancomycin does not reduce deep surgical site infections compared with vancomycin alone (7.4% versus 6.6%; hazard ratio, 1.11) in high-risk tibial fractures [6].

Trial Design and High-Risk Patient Cohort

Previous research has established that intrawound vancomycin powder reduces deep surgical site infections among patients with periarticular tibial fractures at high risk of infection. However, it remained unknown whether adding tobramycin powder would further decrease infection rates by broadening antimicrobial coverage to include gram-negative organisms. To address this clinical question, researchers conducted an open-label, assessor-masked, randomized clinical trial across 39 US trauma centers (registered as NCT02227446). The study focused on a highly vulnerable population: adults with operatively treated periarticular tibial fractures, specifically tibial plateau or pilon injuries. These specific fractures are notoriously prone to infection due to the thin soft tissue envelope surrounding the joint and the high-energy nature of the trauma. Patients were eligible if they met at least one of three criteria for elevated infection risk. During the enrollment period from June 2021 to December 2024, a total of 1660 participants were randomized. After accounting for exclusions, the primary analysis included 1528 participants with a mean age of 47.0 years (standard deviation, 14.3). The cohort comprised 603 female participants (39.5%) and 925 male participants (60.5%), providing a robust sample size to evaluate the efficacy of dual antibiotic powder prophylaxis in orthopedic trauma.

Interventions and Infection Endpoints

To evaluate whether expanding antimicrobial coverage improves outcomes, the researchers compared two specific local antibiotic regimens. Patients randomized to the intervention group received intrawound tobramycin (1.2 g) plus vancomycin (1.0 g) powder delivered directly into the surgical site at the time of definitive fixation. In contrast, patients in the control group received intrawound vancomycin (1.0 g) powder alone. By standardizing the timing and dosing of the local antibiotics, the trial isolated the specific clinical effect of adding an aminoglycoside to standard glycopeptide prophylaxis. The investigators established rigorous clinical endpoints to measure the efficacy of these regimens. The primary outcome was defined as a deep surgical site infection requiring surgical management within 182 days of definitive fracture fixation. This six-month window is clinically significant because it captures both acute postoperative infections and delayed hardware-related infections that necessitate a return to the operating room. Beyond the primary endpoint, the study evaluated several secondary outcomes to capture a comprehensive picture of postoperative complications. These included deep surgical site infections with pathogens that were gram-negative only, infections with at least one gram-positive pathogen, polymicrobial cultures, and negative culture results. Finally, to account for more superficial complications that did not require surgical debridement, the researchers tracked cellulitis or skin infections treated only with antibiotics.

Primary Results and Lack of Superiority

The trial results demonstrated that for patients with high-risk periarticular tibial fractures, adding intrawound tobramycin powder to vancomycin powder at the time of definitive fixation did not reduce deep surgical site infections. For the primary endpoint, deep surgical site infections occurred in 51 of 753 participants in the tobramycin plus vancomycin group, translating to a 182-day probability of 7.4%. In comparison, deep surgical site infections occurred in 47 of 775 participants in the vancomycin alone group, resulting in a slightly lower 182-day probability of 6.6%. Statistical analysis confirmed the lack of benefit from the dual-antibiotic regimen, yielding a hazard ratio of 1.11. The 95% Bayesian credible interval was 0.75 to 1.66 (a statistical range indicating where the true effect size is most likely to fall given the observed data). Furthermore, the posterior probability of superiority for the tobramycin plus vancomycin group was 29.7%. This metric represents the calculated likelihood that the combination therapy is truly better than the control based on the trial data, and it fell well short of the threshold needed to prove clinical benefit. This lack of efficacy extended beyond the primary endpoint, as the threshold required for superiority was not reached for any secondary outcome, including infections driven by specific gram-negative or gram-positive pathogens. For practicing orthopedic surgeons, these findings suggest that routine addition of intrawound tobramycin to vancomycin is unnecessary for periarticular tibial fractures, allowing clinicians to avoid the added costs and potential local tissue toxicity of a second antibiotic agent without compromising infection prevention.

References

1. Jiang N, Chen P, Liu G, et al. Clinical characteristics, treatment and efficacy of calcaneal osteomyelitis: a systematic review with synthesis analysis of 1118 reported cases. International Journal of Surgery. 2024. doi:10.1097/js9.0000000000001815

2. Vanvelk N, Morgenstern M, Moriarty TF, Richards RG, Nijs S, Metsemakers W. Preclinical in vivo models of fracture-related infection: a systematic review and critical appraisal. European Cells and Materials. 2018. doi:10.22203/ecm.v036a14

3. Jacob CC, Daw JH, Santiago-Torres JE. The efficacy of antibiotic-impregnated calcium sulfate (AICS) in the treatment of infected non-union and fracture-related infection: a systematic review. Journal of Bone and Joint Infection. 2023. doi:10.5194/jbji-8-91-2023

4. Lameire DL, Soeder J, Khalik HA, et al. Local vancomycin administration in Orthopaedic Surgery - A systematic review of comparative studies. Journal of Orthopaedics. 2024. doi:10.1016/j.jor.2024.03.040

5. Gandhi M, Balaji G, Menon J, Thomas RR. Does topical vancomycin prevent fracture-related infections in closed fractures undergoing open reduction and internal fixation? A randomised controlled trial. Chinese Journal of Traumatology. 2023. doi:10.1016/j.cjtee.2023.11.006

6. O'Toole RV, O'Hara NN, Carlini AR, et al. Intrawound Tobramycin Plus Vancomycin to Prevent Surgical Site Infection in Tibial Fractures: The TOBRA Randomized Clinical Trial.. JAMA. 2026. doi:10.1001/jama.2026.4023